JNJ-88998377

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-88998377, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]